Research
Hormonal
Tirzepatide (5, 10, and 15 mg weekly) improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis.
If you have moderate to severe fatty liver disease (MASH) with scarring (fibrosis), tirzepatide (5-15 mg weekly) can help resolve the liver inflammation and scarring in about 62% of patients at the highest dose, without making the scarring worse.
GoodSupportsHIGH confidence
treatment with tirzepatide (5, 10 and 15 mg weekly) compared with placebo for 52 weeks in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and stage F2 or F3 (moderate or severe) fibrosis resulted in disease improvement in a dose-dependent fashion. in the tirzepatide 15 mg group, 62% of participants demonstrated resolution of histopathological features of MASH without worsening of liver fibrosis at trial completion (difference 53%; 95% ci 37 to 69%; p < 0.001).
Why this rating
Based on phase 3 trial data (SURMOUNT-2/MASH trial), which is high quality but specific to a subset of patients.
Source
Medical management of obesity: unlocking the potential
Angie S. Xiang et al. · Climacteric · 2025
DOI 10.1080/13697137.2025.2455177
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- New-generation incretin-based obesity medications (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) achieve mean weight loss exceeding 10-15%, which is two- to three-fold greater than previous obesity medications.Strong
- GLP-1 receptor agonists (semaglutide, tirzepatide) provide significant cardiovascular benefits, including a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and pre-existing cardiovascular disease but without diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →